In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...
AI and Early Detection of Dementia: Advancing Life Science Frontiers
Dementia continues to pose a significant challenge in neuroscience and clinical care, affecting millions worldwide. Early detection is pivotal in slowing disease progression and implementing preventive interventions. Life sciences are increasingly leveraging...
AI Giants Nvidia, Microsoft and Google Drive Innovation in Pharma R&D
The intersection of artificial intelligence (AI) and pharmaceutical research is transforming drug discovery, clinical trials, and healthcare innovation. Leading technology companies Nvidia, Microsoft, and Google are spearheading this evolution, applying advanced AI...
Claude for Life Sciences – Major AI Pivot into Drug Discovery and Research
Artificial intelligence company Anthropic is making a significant move into the life sciences sector with the launch of Claude for Life Sciences, a version of its Claude language model platform tailored for scientific research, drug discovery and regulatory workflows....
Microsoft’s Copilot Set to License Harvard Medical School Content
Microsoft is reportedly preparing a major update to its Copilot AI assistant that will let it draw on licensed medical content from Harvard Health Publishing when responding to user queries about healthcare. The development signals a strategic shift toward embedding...
Hyperfine Banks on $17.5 Million Public Stock Offering
Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...
Hyperfine Banks on $17.5 Million Public Stock Offering
Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...






